Open AccessAntidyslipidemic Potential of Water-Soluble Polysaccharides of Ganoderma applanatum in MACAPOS-2-Induced Obese Rats
Author(s) -
Adamou Mfopa,
Francine Mediesse Kengne,
Clémence Mvongo,
Sandrine Nkoubatchoundjwen,
Ambe A. Lum,
Eugène Sobngwi,
René Kamgang,
Thaddée Boudjeko
Publication year - 2021
Publication title -
evidence-based complementary and alternative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.552
H-Index - 90
eISSN - 1741-4288
pISSN - 1741-427X
DOI - 10.1155/2021/2452057
Subject(s) - dyslipidemia , obesity , triglyceride , weight gain , medicine , cholesterol , high density lipoprotein , endocrinology , chemistry , traditional medicine , food science , body weight
Increased consumption of high-calorie foods leads to obesity usually associated with metabolic disorders including diabetes, hyperglycemia, and dyslipidemia. Ganoderma applanatum is a nonedible mushroom traditionally used in West Cameroon for the treatment of many diseases including hypertension, diabetes, and hepatitis. This study was designed to investigate the antidyslipidemic potential of water-soluble polysaccharides of G. applanatum in MACAPOS-2- (maize, cassava, palm oil, and sugar) induced obese rats. For this purpose, obesity was induced on 6–8-week-old male Wistar rats with a local high-fat diet for four months. G. applanatum polysaccharides (GAPs) obtained by hot water extraction were orally administered to obese rats for two months at different dose levels (50, 100, and 150 mg/kg bodyweight), and its potential was investigated on food consumption, bodyweight gain, serum, and tissue lipids parameters. GAP extract increased the bodyweight gain by raising the food intake of obese rats. Furthermore, the administration of GAP extract at different dose levels significantly decreased the total cholesterol, triglyceride, low-density lipoprotein cholesterol levels, and the atherogenic index from 50 to 150 mg/kg bodyweight. Conversely, GAP extract improved the high-density lipoprotein cholesterol level in obese rats compared with untreated rats after two months' study period. These results indicated that GAP extract may be considered as a novel bioactive compound against dyslipidemia and its associated complications.